All the Active Ingredient Drugs
Immunoglobulins. Trastuzumab deruxtecan 20 mg/ml. Vial. Pwder for sol. for inf.
5.4 mg/kg given as IV infus. once every 3 weeks (21-day cycle) until dis. progression or unacceptable tox. For gastric cancer dose is 6.4 mg/kg .Do not substitute this drug for or with trastuzumab or ado-trastuzumab emtansine.
HER2-Pos. Metast. Breast Cancer: tmt. of adults with unresectable or metast. HER2-pos. (IHC 3+ or ISH pos.) breast cancer who have received a prior anti-HER2-based regim. either:• in the metast. setting, or• in the neoadj. or adj. setting and have developed dis. recurrence during or within six months of completing ther. HER2-Low and HER2-Ultralow Metast. Breast Cancer: tmt. of adults with unresectable or metast.•Hormone receptor (HR)-pos. HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, that has progressed on one or more endocr. ther. in the metast. setting.•HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemother. in the metast. setting or developed dis. recurrence during or within 6 months of completing adj. chemother.HER2-Mutant Unresectable or Metast. Non-Small Cell Lung Cancer:tmt. of adults with unresectable or metast. non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutat., as detected by an approved test, and who have received a prior syst. ther.HER2-Pos. Locally Adv. or Metast. Gastric Cancer: tmt. of adults with locally adv. or metast. HER2-pos. (IHC 3+ or IHC 2+/ISH pos.) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regim. HER2-Positive (IHC 3+) Unresectable or Metast. Solid Tumor: tmt. of adults with unresectable or metast. HER2-pos. (IHC 3+) solid tumors who have received prior syst. tmt. and have no satisfact. alternat. options.
C/I: Hypersens.
